Only an abuse-resistant name-brand formulation of oxycodone will be allowed to remain on the market, according to the US Food and Drug Administration (FDA). In April 2013, the agency withdrew approval of the original form of the drug and noted that it will not accept generic drug applications from companies seeking to reproduce the original formulation.
The FDA approved a version of oxycodone in April 2010 that is more difficult to crush, break, or dissolve; it forms a hydrogel when wet, making it more difficult to abuse via snorting or injecting, according to the FDA. The drug's maker stopped selling the original version later that year. Along with the new statement, the FDA announced updated labeling on the reformulated version, highlighting its abuse-resistant properties.
Kuehn BM. Safer Oxycodone. JAMA. 2013;309(20):2087. doi:10.1001/jama.2013.5921
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: